– NETHERLANDS, Amsterdam – Scenic Biotech BV, a pioneer in the discovery of genetic modifiers today announced it has closed a €28 million Series A financing round co-led by Eir Ventures, BioMedPartners, and Vesalius Biocapital alongside existing investors Inkef Capital, BioGeneration Ventures, and Oxford Science Enterprises also participating.
Concurrent with the financing, Dr. Stephan Christgau (Ph.D.) General Partner Eir Ventures, Dr. Michael Wacker (Ph.D.), General Partner BioMedPartners, and Stephane Verdood, Managing Partner Vesalius Biocapital will join the board of directors.
The funds will be used to accelerate the transition into a development stage company, advancing its in-house pipeline and supporting the creation of new programs based on its Cell-Seq genetic modifier target discovery platform including new industry collaborations.
Stephan Christgau said, “Scenic Biotech has the potential to become one of Europe’s most exciting biotech companies. It is a pioneer in the ground-breaking and promising new field of genetic modifiers. We are impressed by the power of its Cell-Seq platform and how it’s fueling a portfolio of in-house and partnered programs across multiple therapeutic areas. This financing will enable Scenic to continue to develop its platform and move its lead program into human clinical trials while bringing its rare disease programs to key-value infection points.”
For more information: https://scenicbiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.